SPDE Speedus Corp (CE)

White Paper 'Computer Aided Auscultation of the Heart, the Clinical Opportunity' Available at Zargis Website PRINCETON, N.J., Nov. 29 /PRNewswire-FirstCall/ -- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), announced today it has released a white paper that summarizes the state of the art in cardiac auscultation, reviews the clinical challenges and opportunities, and evaluates the use of echocardiography in the assessment of patients with heart murmurs. The paper also describes computer aided auscultation in detail and assesses the clinical utility of such a system. This white paper was commissioned by Zargis and written by Apothecom Associates, LLC located in Yardley, PA and can be accessed by visiting the Zargis website at http://www.zargis.com/ or by sending an email request to . "Apothecom has done an excellent job of consolidating and commenting on more than 70 published research articles in the area of auscultation. After reading this white paper, one understands the merits of Zargis' research and development efforts as well as our value proposition to clinicians and to the healthcare system in general." commented John Kallassy, the Managing Director of Zargis Medical. About Zargis Medical Corp. Zargis Medical Corp. was formed in January 2001 when Siemens Corporate Research Inc., a subsidiary of Siemens AG (NYSE:SI), and Speedus Corp. (NASDAQ:SPDE) co-invested in Zargis to further develop and commercially market an advanced acoustic technology for detecting abnormalities identified through analysis of heart sounds. Based in Princeton, New Jersey, Zargis is developing advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis has developed Cardioscan, the first and only FDA approved computer- assisted medical device to support physicians in analyzing heart sounds for the identification of suspected murmurs, a potential sign of heart disease. Cardioscan is easy to use, non-invasive, portable, and takes just minutes to perform. Developed by scientists from Siemens and Zargis over many years, Cardioscan implements voice-guided protocol and graphical user interface while maintaining an efficient physician workflow. The system provides a summary of findings in terms that are readily understood by physicians with more quantitative auscultatory information than is possible through listening alone. Thus, Cardioscan enhances auscultation which has been universally employed through a stethoscope for nearly two hundred years. For additional information on Speedus Corp. or Zargis Medical, contact John Kallassy, 718.567.4358, , or visit their websites at http://www.speedus.com/ and http://www.zargis.com/. For additional information on Siemens Corporate Research, visit their website at http://www.scr.siemens.com/. Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward- looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts. DATASOURCE: Zargis Medical Corp. CONTACT: John Kallassy for Zargis Medical Corp., +1-718-567-4358, Web site: http://www.speedus.com/ http://www.zargis.com/ http://www.scr.siemens.com/

Copyright